ArticleClinical epigenetics2026
DNA methylation-mediated silencing of HNF1B promotes bladder cancer progression.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocyte nuclear factor 1 homeobox B (HNF1B), a developmentally crucial transcription factor, demonstrates tumor-suppressive functions in several cancers, with epigenetic silencing being a known mechanism, as seen in malignancies like ovarian and prostate carcinoma. Its functional significance in bladder cancer pathogenesis is far less clear.
resultsOur analysis of clinical cohorts identified low HNF1B expression as an independent prognostic factor that is significantly associated with adverse clinicopathological characteristics and poorer survival in bladder cancer patients. Functionally, knockdown of HNF1B promoted bladder cancer cell proliferation, migration, and invasion, whereas its overexpression suppressed these malignant phenotypes in vitro and attenuated tumor growth in vivo. Mechanistically, HNF1B silencing was primarily mediated by promoter hypermethylation. Furthermore, we demonstrated that HNF1B exerts its tumor-suppressive roles by concurrently inhibiting the mitogen-activated protein kinase (MAPK) signaling pathway and the epithelial-mesenchymal transition (EMT) process.
conclusionOur study unveils a novel epigenetic mechanism in bladder cancer, whereby promoter hypermethylation silences HNF1B, thereby promoting tumor progression through activation of the MAPK pathway. These findings establishe HNF1B status as a potential biomarker for stratifying patients who may benefit from targeted therapies against this pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.